Ceftaroline

Active ingredient: Ceftaroline Fosamil

In short: Ceftaroline fosamil for injection is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negativ

Forms & strengthsFor Injection: Ceftaroline fosamil for injection is supplied as 600 mg or 400 mg of sterile ceftaroline fosamil (equivalent to 653 mg and 435 mg, respectively, of ceftaroline fosamil monoacetate) powder in single-dose, 20 mL clear glass vials. …
LabelApotex Corp.
Label updatedOct 16, 2026

What is Ceftaroline used for?

Ceftaroline fosamil for injection is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca .

Ceftaroline fosamil for injection is indicated in adult and pediatric patients 2 months of age and older for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftaroline fosamil for injection and other antibacterial drugs, ceftaroline fosamil for injection should be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. …

Ceftaroline dosage

The recommended dosage of ceftaroline fosamil for injection is 600 mg administered every 12 hours by intravenous (IV) infusion over 5 to 60 minutes in patients ≥18 years of age. The duration of therapy should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress.

The recommended dosage and administration by infection is described in Table 1.

Table 1: Dosage of Ceftaroline Fosamil for Injection by Indication in Adults

Indication | Dosage | Frequency | Infusion Time | Recommended Duration of Treatment

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | 600 mg | Every 12 hours | 5 to 60 minutes | 5-14 days

Community-Acquired Bacterial Pneumonia (CABP) | 600 mg | Every 12 hours | 5 to 60 minutes | 5-7 days

The recommended dosage of ceftaroline fosamil for injection in pediatric patients is based on the age and weight of the child. The duration of therapy should be guided by the severity, site of infection and the patient’s clinical and bacteriological progress.

Pediatric Patients 2 Months of Age and Older

For pediatric patients 2 months of age and older, ceftaroline fosamil for injection is administered every 8 hours by intravenous infusion over 5 to 60 minutes.

Ceftaroline fosamil for injection dosing regimen is dependent on the type of infection (ABSSSI, CABP). See dosing Table 2 below.

Table 2:

Dosage of Ceftaroline Fosamil for Injection by Indication in Pediatric Patients 2 Months of Age and Older

Indication | Age Range | Dosage and Frequency | Infusion time | Recommended Duration of Treatment

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) OR Community-Acquired Bacterial Pneumonia (CABP) | 2 months to < 2 years | 8 mg/kg every 8 hours | 5 to 60 minutes | 5-14 days

≥ 2 years to < 18 years (≤ 33 kg) | 12 mg/kg every 8 hours

≥ 2 years to < 18 years (> 33 kg) | 400 mg every 8 hours OR 600 mg every 12 hours

Pediatric Patients Less Than 2 Months of Age

Ceftaroline fosamil for injection are administered every 8 hours by intravenous infusion over 30 to 60 minutes for patients less than 2 months of age.

Ceftaroline fosamil for injection dosing regimen is only recommended for patients with ABSSSI. See dosing Table 3 below.

Concentrations of ceftaroline fosamil in the cerebrospinal fluid have not been evaluated .

There is no information for dosing ceftaroline fosamil for injection in infants less than 34 weeks gestational age and less than 12 days postnatal age. …

How to take Ceftaroline — instructions & advice from the label

Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. They should inform their healthcare provider about any previous hypersensitivity reactions to ceftaroline fosamil for injection, other beta-lactams (including cephalosporins) or other allergens.

Advise patients that neurological adverse reactions could occur with ceftaroline fosamil for injection use. Instruct patients or their caregivers to inform their healthcare provider at once of any neurological signs and symptoms, including encephalopathy (disturbance of consciousness including somnolence, lethargy, confusion, and slow thinking), and seizures for immediate treatment, dosage adjustment, or discontinuation of ceftaroline fosamil for injection.

Patients should be counseled that antibacterial drugs including ceftaroline fosamil for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). …

Warnings & precautions

Do not take this medicine if: Ceftaroline fosamil for injection is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. Anaphylaxis has been reported with ceftaroline.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with ceftaroline fosamil for injection is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. Maintain clinical supervision if this product is to be given to a penicillin- or other beta-lactam-allergic patient, because cross sensitivity among beta-lactam antibacterial agents has been clearly established.

If an allergic reaction to ceftaroline fosamil for injection occurs, discontinue ceftaroline fosamil for injection and institute appropriate treatment and supportive measures.

Clostridioides

difficile-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ceftaroline fosamil for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. …

Ceftaroline side effects

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section

Hypersensitivity Reactions

Clostridioides difficile-Associated diarrhea

Neurological Adverse Reactions

Direct Coombs’ Test Seroconversion

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared directly to rates from clinical trials of another drug and may not reflect rates observed in practice.

Adult Patients

Ceftaroline fosamil for injection was evaluated in four controlled comparative Phase 3 clinical trials (two in ABSSSI and two in CABP) which included 1,300 adult patients treated with ceftaroline fosamil for injection (600 mg administered by IV over 1 hour every 12h) and 1,297 patients treated with comparator (vancomycin plus aztreonam or ceftriaxone) for a treatment period up to 21 days. The median age of patients treated with ceftaroline fosamil for injection was 54 years, ranging between 18 and 99 years old. Patients treated with ceftaroline fosamil for injection were predominantly male (63%) and Caucasian (82%).

Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation

In the four pooled adult Phase 3 clinical trials, serious adverse reactions (SARs) occurred in 98/1,300 (7.5%) of patients receiving ceftaroline fosamil for injection and 100/1,297 (7.7%) of patients receiving comparator drugs. …

About this medicine

Ceftaroline fosamil for injection is a sterile, semi-synthetic, prodrug of the cephalosporin antibacterial class of beta-lactams (β- lactams). Chemically, the prodrug, ceftaroline fosamil monoacetate is (6R,7R)-7-{(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido}-3-{[4-(1-methylpyridin-1-ium-4- yl)-1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monoacetate. Its molecular weight is 744.74. The molecular formula is C22H21N8O8PS4. CH3COOH.

Figure 1: Chemical structure of ceftaroline fosamil

Ceftaroline fosamil for injection vials contain either 600 mg or 400 mg of anhydrous ceftaroline fosamil (equivalent to 653 mg and 435 mg, respectively, of ceftaroline fosamil monoacetate). The powder for injection is formulated from ceftaroline fosamil monoacetate, a yellow white to light yellow powder. Each vial of 400 mg of anhydrous ceftaroline fosamil includes inactive ingredient L-arginine 264 mg/vial as buffering agent. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9ec2cc88-fbec-a5aa-df85-ecff7350d813. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin